AtG Therapeutics
Overcoming Tumor Adaptation - inhibiting escape mechanisms both in treatment naive and resistant patients
Overcoming Tumor Adaptation - inhibiting escape mechanisms both in treatment naive and resistant patients
AtG Therapeutics is a biotechnology startup founded in 2021 and headquartered in Spain. The company's mission is succinctly captured by its slogan, "Overcoming Tumor Adaptation - inhibiting escape mechanisms both in treatment naïve and resistant patients." AtG Therapeutics focuses on pre-clinical stage drug development, specializing in the discovery of targets of tumor adaptation vulnerabilities and the development of therapeutics and biomarkers to treat advanced cancer.
In July 2022, AtG Therapeutics secured a significant milestone with a €556.00K Seed Round investment from notable investors including Inveniam, WA4STEAM, and Blue Goose Capital. This infusion of capital is expected to propel the company's research and development efforts and advance its promising solutions for patients grappling with advanced cancer.
AtG Therapeutics' innovative approach to tackling the challenges of treating advanced cancer, combined with its recent successful fundraising efforts, positions the company as a compelling player in the biotechnology and healthcare industries. With a focus on disrupting the status quo and addressing the unmet needs of cancer patients, AtG Therapeutics is a company to watch in the evolving landscape of oncology therapeutics.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | €556.00K | 3 |
|
21 Jul 2022 |
No recent news or press coverage available for AtG Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
